TORONTO, ON and NEW YORK, NY / ACCESSWIRE / November 7, 2024 / Bionoid Pharma, Inc. ("BINP") (OTC PINK:BINP) is pleased to announce the formal engagement of Olayinka Oyebola & Co., a PCAOB-registered ...

Split Becomes Effective Monday, November 11, 2024Shareholder- and Board-Approved Action Reduces Shares Outstanding to 313,235 from 31 Million, Ensures Continued Compliance with Nasdaq Listing ...

Quarter Results07.11.2024 / 12:30 CET/CESTThe issuer is solely responsible for the content of this announcement.Immunic, Inc. Reports Third Quarter 2024 Financial Resultsand Provides Corporate Update– ...

Bristol Myers Squibb today announced the appointment of Karen Costello as the new General Manager for its commercial operations in Ireland. In this new role, Karen will lead the delivery of Bristol ...

Professor Meritxell Huch, a director at the Max Planck Institute of Molecular Cell Biology and Genetics, Dresden, Germany receives this year’s Otto Bayer Award for her pioneering research on human ...

The UK Dementia Research Institute has today announced multimillion major new government funding to “supercharge” advances in research and develop and deliver new solutions for people living with or ...

The NHS Business Services Authority (NHSBSA) has released the latest report on Prescribing Costs in Hospitals and the Community for England in 2023/24. The report provides a national view of ...

PulseSight Therapeutics SAS, an ophthalmology biotech company developing disruptive non-viral vectorized therapies with minimally-invasive delivery technology, has presented new data on its lead ...

New research into a chemical produced by a caterpillar fungus that has shown promise as a possible cancer treatment has revealed how it interacts with genes to interrupt cell growth signals. The ...

Scottish scientists have developed a low-cost, flexible device that can help prevent blood clots for patients after an operation.

Study will investigate the benefits of combining Lisata's novel product candidate, certepetide, with ValoTx's platform technology, PeptiCRAd, and a checkpoint inhibitor in preclinical tumor models ...

The third quarter of 2024 presented Genmab with additional opportunities to progress towards our goal of fundamentally transforming the lives of people with cancer and other serious diseases. The ...